121 related articles for article (PubMed ID: 26197202)
1. Pharmacologic inhibition of intestinal sodium uptake: a gut centric approach to sodium management.
Spencer AG; Greasley PJ
Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):410-6. PubMed ID: 26197202
[TBL] [Abstract][Full Text] [Related]
2. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
Spencer AG; Labonte ED; Rosenbaum DP; Plato CF; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Bell N; Tabora J; Joly KM; Navre M; Jacobs JW; Charmot D
Sci Transl Med; 2014 Mar; 6(227):227ra36. PubMed ID: 24622516
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
[TBL] [Abstract][Full Text] [Related]
6. Gut hormones and gut microbiota: implications for kidney function and hypertension.
Afsar B; Vaziri ND; Aslan G; Tarim K; Kanbay M
J Am Soc Hypertens; 2016 Dec; 10(12):954-961. PubMed ID: 27865823
[TBL] [Abstract][Full Text] [Related]
7. The importance of intake: a gut feeling.
Gerritsen KG; Boer WH; Joles JA
Ann Transl Med; 2015 Mar; 3(4):49. PubMed ID: 25861604
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic treatment of hypertension in patients with chronic kidney disease.
Talreja H; Ruzicka M; McCormick BB
Am J Cardiovasc Drugs; 2013 Jun; 13(3):177-88. PubMed ID: 23553321
[TBL] [Abstract][Full Text] [Related]
9. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
Johansson SA; Knutsson M; Leonsson-Zachrisson M; Rosenbaum DP
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):457-465. PubMed ID: 28339149
[TBL] [Abstract][Full Text] [Related]
10. Hypertension in CKD: Sodium still at the nexus.
Yee J
Adv Chronic Kidney Dis; 2015 May; 22(3):173-6. PubMed ID: 25908464
[No Abstract] [Full Text] [Related]
11. Novel Treatments from Inhibition of the Intestinal Sodium-Hydrogen Exchanger 3.
Kovesdy CP; Adebiyi A; Rosenbaum D; Jacobs JW; Quarles LD
Int J Nephrol Renovasc Dis; 2021; 14():411-420. PubMed ID: 34880650
[TBL] [Abstract][Full Text] [Related]
12. The Myth of Water and Salt: From Aquaretics to Tenapanor.
Visconti L; Cernaro V; Calimeri S; Lacquaniti A; De Gregorio F; Ricciardi CA; Lacava V; Santoro D; Buemi M
J Ren Nutr; 2018 Mar; 28(2):73-82. PubMed ID: 29146141
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Salt Intake, Urinary Sodium Excretion and Their Relationship to Overhydration in Chronic Kidney Disease Patients.
Hallvass AE; Claro LM; Gonçalves S; Olandoski M; Nerbass FB; Aita CA; de Moraes TP; Pecoits-Filho R
Blood Purif; 2015; 40(1):59-65. PubMed ID: 26138081
[TBL] [Abstract][Full Text] [Related]
14. Renal function in NHE3-deficient mice with transgenic rescue of small intestinal absorptive defect.
Woo AL; Noonan WT; Schultheis PJ; Neumann JC; Manning PA; Lorenz JN; Shull GE
Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1190-8. PubMed ID: 12582007
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of resistant hypertension in chronic kidney disease.
Campese VM
Semin Nephrol; 2014; 34(5):571-6. PubMed ID: 25416666
[TBL] [Abstract][Full Text] [Related]
16. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
Alcázar Arroyo R
Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na
Jacobs JW; Leadbetter MR; Bell N; Koo-McCoy S; Carreras CW; He L; Kohler J; Kozuka K; Labonté ED; Navre M; Spencer AG; Charmot D
ACS Med Chem Lett; 2022 Jul; 13(7):1043-1051. PubMed ID: 35859876
[TBL] [Abstract][Full Text] [Related]
18. Tenapanor: First Approval.
Markham A
Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
Currò D; Ianiro G; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):889-894. PubMed ID: 38108081
[TBL] [Abstract][Full Text] [Related]
20. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD.
Ruzicka M; Quinn RR; McFarlane P; Hemmelgarn B; Ramesh Prasad GV; Feber J; Nesrallah G; MacKinnon M; Tangri N; McCormick B; Tobe S; Blydt-Hansen TD; Hiremath S
Am J Kidney Dis; 2014 Jun; 63(6):869-87. PubMed ID: 24725980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
